| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Products Intro: |
Product Name:AbcixiMab
CAS:143653-53-6
Purity:Typically NLT 98%
|
|
| | abciximab Basic information |
| Product Name: | abciximab | | Synonyms: | Rheopro;Immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhCgamma1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VkappahCkappa light chain;CentoRx;Unii-X85G7936gv;Reopro;Research Grade Abciximab(DHC33301);Abcixifiban;c7E3 Fab | | CAS: | 143653-53-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![abciximab Structure]() |
| | abciximab Chemical Properties |
| storage temp. | Store at -80°C |
| | abciximab Usage And Synthesis |
| Uses | Monoclonal antibody
(antithrombotic). | | Brand name | ReoPro (Lilly). | | Clinical Use | Antiplatelet agent:
Prevention of ischaemic cardiac complications
in patients undergoing percutaneous coronary
intervention
Short-term prevention of myocardial infarction
in patients with unstable angina not responding
to treatment or awaiting percutaneous coronary
intervention. | | Enzyme inhibitor | This antithrombotic (MW = 47455 g/mol; CAS 143653-53-6; also known as Reopro?) consists of an immunoglobulin G1 Fab fragment from a chimeric human-murine monoclonal antibody directed against the human platelet glycoprotein IIb/IIIa receptor. Abciximab also facilitates the dispersal of newly formed platelet aggregates in vitro, by partially displacing fibrinogen from activated GPIIb/IIIareceptors. In vivo, abciximab may destabilize coronary thrombi by preventing aggregate formation and dispersing mural thrombi. Target(s): coagulation factor Xa, in presence of heparin; glycoprotein IIb/IIIa receptor. | | Drug interactions | Potentially hazardous interactions with other drugs
Heparin, anticoagulants, antiplatelets and
thrombolytics: increased risk of bleeding. | | Metabolism | Following IV administration, abciximab rapidly binds
to the platelet GPIIb/IIIa receptors, and remains in the
circulation for 15 days or more in a platelet-bound state.
Metabolism is via proteolytic cleavage |
| | abciximab Preparation Products And Raw materials |
|